MDXG
Mimedx Group, Inc.
$4.27
+0.07 (+1.67%)
At close · Jul 15
Market Cap
$636.00M
Shares
148,945,731
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$418.63M
+20%
FY2025
Net Income
$48.58M
+14.5%
FY2025
Gross Margin
82.56%
-0.2pp
FY2025
Operating Margin
15.26%
-1.6pp
FY2025
Diluted EPS
$0.32
+14.3%
FY2025
Operating Cash Flow
$74M
+11.8%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $260M – $290M | $389.42M | $418.63M | $348.88M | $321.48M | $267.84M | $258.62M | $248.23M | $299.26M | $359.11M | — | — | — | — | — | $7.76M | |
| — | -$6.59M | — | — | -$6.46M | -$5.02M | -$4.98M | -$7.94M | -$4.71M | -$339K | — | — | — | — | — | — | |
| — | $73.82M | $73.01M | $60.07M | $54.63M | $48.32M | $43.28M | $39.33M | $43.08M | $36.39M | $32.41M | $20.2M | $12.67M | $9.33M | $5.19M | $3.15M | |
| — | $315.59M | $345.62M | $288.81M | $266.84M | $219.53M | $215.33M | $208.9M | $256.17M | $322.73M | $212.61M | $167.09M | $105.56M | $49.85M | — | — | |
| — | — | 82.56% | 82.78% | 83.01% | 81.96% | 83.26% | 84.16% | 85.6% | 89.87% | — | — | — | — | — | — | |
| — | $15.91M | $15.1M | $12.34M | $12.67M | $22.83M | $17.34M | $11.72M | $11.14M | $15.77M | $12.04M | $8.41M | $7.05M | $4.84M | $2.88M | $2.6M | |
| — | $206.73M | $209.68M | $175.56M | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $52.72M | $56.51M | $49.53M | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $259.46M | $266.19M | $225.09M | $211.12M | $208.79M | $198.36M | $181.02M | $198.21M | $258.53M | $180M | $133.38M | $90.48M | $46.23M | $20.97M | $11.76M | |
| — | $641K | $439K | $765K | $762K | $701K | $820K | $1.07M | $1.04M | $1.03M | $2.13M | $933K | $928K | $1.05M | $1.38M | $1.34M | |
| — | — | $14.88M | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | $0 | $0 | $0 | $8.54M | $6.06M | — | — | — | — | — | — | |
| — | $39.59M | $63.89M | $58.87M | $37.12M | -$24.97M | -$5.04M | -$45.4M | -$21.16M | -$3.92M | $18.45M | $24.36M | $7.1M | -$2.64M | -$5.36M | -$9.76M | |
| — | — | 15.26% | 16.87% | 11.55% | -9.32% | -1.95% | -18.29% | -7.07% | -1.09% | — | — | — | — | — | -125.78% | |
| — | — | $78.77M | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $1.71M | $1.78M | $3.94M | — | — | — | — | — | — | $339K | $86K | $48K | $45.23K | $592.89K | $432.97K | |
| — | $5.02M | $4.72M | $2.93M | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | -$581K | -$558K | -$565K | -$26K | -$4000 | -$23K | -$3000 | $283K | $527K | — | — | — | — | — | — | |
| — | $42.32M | $66.26M | $57.29M | $30.63M | -$29.99M | -$10.04M | -$61.54M | -$25.59M | -$3.4M | $18.11M | $24.28M | $7.05M | -$4.01M | -$7.66M | -$10.19M | |
| — | $11.62M | $17.68M | $15.3M | -$36.81M | $206K | $247K | -$12.26M | -$5000 | $26.58M | $6.13M | -$5.17M | $832K | $99.61K | $0 | $0 | |
| — | $30.7M | $48.58M | $42.42M | $58.23M | -$30.2M | -$10.29M | -$49.28M | -$25.58M | -$29.98M | $11.97M | $29.45M | $6.22M | -$4.11M | -$7.66M | -$10.19M | |
| — | — | 11.6% | 12.16% | 18.11% | -11.27% | -3.98% | -19.85% | -8.55% | -8.35% | — | — | — | — | — | -131.36% | |
| — | -$2.54M | — | — | — | -$36.78M | -$16.42M | -$83.33M | — | — | — | — | — | — | — | — | |
| USD/shares | — | — | $0.33 | $0.29 | $0.40 | -$0.33 | -$0.15 | -$0.77 | -$0.24 | -$0.28 | $0.11 | $0.28 | $0.06 | — | — | — |
| USD/shares | — | — | $0.32 | $0.28 | $0.37 | -$0.33 | -$0.15 | -$0.77 | -$0.24 | -$0.28 | $0.11 | $0.26 | $0.05 | — | — | — |
| shares | — | — | 147.79M | 146.98M | 116.5M | 112.91M | 110.35M | 108.26M | 106.95M | 105.6M | 105.93M | 105.93M | 105.79M | 96.29M | 81.65M | — |
| shares | — | — | 149.72M | 149.05M | 145.96M | 112.91M | 110.35M | 108.26M | 106.95M | 105.6M | 112.44M | 113.63M | 113.3M | 96.29M | 81.65M | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2015–FY2025: $76.1M in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
1.27×
Biotechnology median 8.54×
EV/EBIT
12.47×
Biotechnology median 25.59×
P/E (TTM)
21.35×
Biotechnology median 7.55×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|
| Wound Surgical Segment | $264,906,000 | $238,940,000 | $213,489,000 |
| Regenerative Medicine Segment | $0 | $16,596,000 | $32,362,000 |
By Product & Service (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Wound | $276,326,000 | $231,004,000 | $205,660,000 | $175,970,000 | — | — |
| Surgical | $142,304,000 | $117,875,000 | $115,817,000 | $91,871,000 | — | — |
| Advanced Wound Care Tissue and Other | — | — | — | $241,992,000 | — | $192,566,000 |
| Advanced Wound Care Umbilical Cord Derived | — | — | — | $23,211,000 | — | $16,073,000 |
| Hospital Site of Service | — | — | — | $163,206,000 | $142,140,000 | $144,285,000 |
| Other Site of Service | — | — | — | $27,477,000 | $25,357,000 | $28,311,000 |
| Private Office Site of Service | — | — | — | $77,158,000 | $74,522,000 | $75,638,000 |
| Section 351 | — | — | — | $2,379,000 | — | $31,828,000 |
| Health Care | — | — | — | $265,203,000 | — | $208,639,000 |
| Product And Service Other | — | — | — | $259,000 | — | $7,767,000 |
Key facts
CIK
1376339
CUSIP
602496101
13F (30d)
11 filings
11 filers
Visit website
Investor relations